
SPARCSun Pharma Advanced Research Company Ltd.
Sun Pharma Advanced Research Company Q2 FY27 Results: Consolidated Net Loss ₹24.39 Crore on Total Income of ₹53.65 Crore
Sun Pharma Advanced Research Company (NSE: SPARC) reported consolidated total income of ₹53.65 crore and a net loss of ₹24.39 crore for the quarter ended 30 Sep 2026, as stated in its filing of 02 Nov 2026. Standalone total income was the same at ₹53.65 crore, with a net loss of ₹24.58 crore.
- Earnings
- pharmaceutical research and development